Epigenomics Announces Layoffs, Product Line Cancellation in Restructuring
The firm is halting sale of Epi proColon and recalling the product as well as reducing its employee headcount after failing to raise additional capital.
In Brief This Week: SomaLogic, Centogene, Yourgene, Epigenomics, Biodesix, More
News items for the week of Dec. 19, 2022.
The firm has commercialized its pancreatic cancer test and has its sights set on an ovarian cancer test launching in 2023.
Bluestar Genomics to Study Pancreatic Cancer Early Detection Test in Type 2 Diabetes Patients
The firm will evaluate its epigenomic liquid biopsy test to detect pancreatic cancer among patients considered high-risk for the disease due to their diabetes.
Earnings Roundup: OraSure Technologies, LumiraDx, Opko, More
OraSure, LumiraDx, Opko, and Epigenomics reported their financial results this week.
Aug 11, 2021
Epigenomics H1 Revenues Down 31 Percent
Jan 7, 2021
Epigenomics Issues €5.5M Convertible Bond
Nov 12, 2020
Epigenomics Posts 30 Percent Rise in Q3 Revenues
May 7, 2020
Epigenomics Q1 Revenues Down 28 Percent
Apr 29, 2020
Epigenomics Preliminary Q1 Revenues Drop 33 Percent
Nov 19, 2019
Epigenomics Posts 69 Percent Drop in Q3 Revenues
Aug 7, 2019
Epigenomics Q2 Revenues Slide 25 Percent
May 10, 2019
May 8, 2019
Epigenomics Q1 Revenues Rise 7 Percent
Mar 27, 2019